
The study explored neoadjuvant chemotherapy with FOLFIRINOX in resectable pancreatic ductal adenocarcinoma, challenging current standard practices. The trial compared FOLFIRINOX followed by surgery versus surgery and adjuvant chemotherapy, demonstrating potential benefits in improving chemotherapy delivery. Although neoadjuvant therapy is not yet recommended as standard, this study sheds light on its role in optimizing outcomes for high-risk patients.
Like
Save
Share